Lauric Acid

Lauric Acid at a Glance

Lauric acid, or dodecanoic acid (C12:0), is a medium-chain saturated fatty acid and the single most abundant fatty acid in coconut oil and palm-kernel oil, where it makes up roughly half of all the fatty acids present ^{7,9Reference 7Eyres L et al. · 2016Coconut oil consumption and cardiovascular risk factors in humansView study →Reference 9Ghosh PK et al. · 2014Physicochemical and phytochemical analyses of copra and oil of Cocos nucifera L. (West Coast Tall variety)View study →}. It is a dietary and structural lipid — a building block of fats and cell membranes — not a therapeutic isolate.

What sets it apart chemically is a genuinely well-documented antimicrobial activity: among common fatty acids, lauric acid and its monoglyceride monolaurin (glycerol monolaurate) are repeatedly the most active against bacteria and enveloped viruses in laboratory work ^{1Reference 1Kabara JJ et al. · 1972Fatty acids and derivatives as antimicrobial agentsView study →}. That is a real, verifiable hook — unlike the vague “detected by GC-MS” attributions common to minor plant fatty acids.

Two honest caveats frame everything below. First, its metabolism sits between a true medium-chain fat and a long-chain one — so the popular marketing of coconut oil as an “MCT” fat overstates the case ^{11Reference 11Sigalet DL · 1999Lymphatic absorption of glucose and fatty acids as determined by direct measurementView study →}. Second, as a dietary saturated fat it raises LDL cholesterol (while also raising HDL), so the antimicrobial story does not make it a health food ^{6,7Reference 6Mensink RP et al. · 2003Meta-analysisEffects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trialsView study →Reference 7Eyres L et al. · 2016Coconut oil consumption and cardiovascular risk factors in humansView study →}.

The Antimicrobial Fatty Acid

The compound-defining property of lauric acid is its antimicrobial activity, first mapped systematically by Jon Kabara in 1972. Testing a wide series of fatty acids and their derivatives, Kabara found that among saturated fatty acids lauric acid (C12) was the most active antibacterial, and that its monoglyceride, monolaurin, was more active still — a finding that has anchored the field ever since ^{1Reference 1Kabara JJ et al. · 1972Fatty acids and derivatives as antimicrobial agentsView study →}.

The activity is broad but selective: lauric acid and monolaurin are most effective against Gram-positive bacteria and lipid-enveloped viruses, whose membranes the free fatty acid and its monoglyceride disrupt, while Gram-negative bacteria (with their outer membrane) are largely spared ^{1Reference 1Kabara JJ et al. · 1972Fatty acids and derivatives as antimicrobial agentsView study →}. In dermatology this has been pursued against acne — lauric acid shows strong activity against Cutibacterium (Propionibacterium) acnes in vitro, in one study out-performing benzoyl peroxide on a molar basis, and liposome-encapsulated lauric acid was proposed as an anti-acne agent ^{2,3Reference 2Nakatsuji T et al. · 2009Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgarisView study →Reference 3Yang D et al. · 2009The antimicrobial activity of liposomal lauric acids against Propionibacterium acnesView study →}. Sebum free fatty acids including lauric acid also upregulate the antimicrobial peptide human β-defensin-2 in skin sebocytes, feeding the skin’s own innate defence ^{4Reference 4Nakatsuji T et al. · 2010Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating β-defensin-2 expressionView study →}.

Its monoglyceride is the commercial face of this chemistry: monolaurin / glycerol monolaurate is sold as an antimicrobial-antiviral supplement, and is virucidal against enveloped viruses in laboratory assays ^{5Reference 5Welch JL et al. · 2020Glycerol monolaurate, an analogue to a factor secreted by Lactobacillus, is virucidal against enveloped viruses, including HIV-1. mBio. https://pubmed.ncbi.nlm.nih.gov/32371599/View study →}. The important limitation is that almost all of this is in-vitro or topical evidence — there is no established record of oral lauric acid or monolaurin curing systemic infection in humans.

Medium-Chain or Long-Chain? The MCT Question

Lauric acid is routinely called a medium-chain fatty acid on carbon count (C12), and coconut oil is marketed as a source of MCTs — but the metabolism tells a more nuanced story that is worth stating honestly.

The true medium-chain fatty acids, caprylic (C8) and capric (C10) acid, are absorbed largely unesterified via the portal vein straight to the liver, where they are rapidly oxidised — the property that makes purified MCT oil metabolically distinctive. Lauric acid behaves only partly this way. A substantial fraction (commonly cited around 70-75%) is instead re-esterified into triglycerides and carried in chylomicrons through the lymphatic system, the route of a long-chain fat ^{11Reference 11Sigalet DL · 1999Lymphatic absorption of glucose and fatty acids as determined by direct measurementView study →}. So although it is a “medium-chain” fat by chemistry, it does not deliver the clean portal-vein, rapid-oxidation kinetics that MCT marketing implies — a point reviews of coconut oil make explicitly ^{7Reference 7Eyres L et al. · 2016Coconut oil consumption and cardiovascular risk factors in humansView study →}.

This matters commercially: much of the “MCT” credited to coconut oil is actually lauric acid, which functions more like a conventional dietary fat than like C8/C10 MCT oil.

What It's Used For

Beyond its antimicrobial signature, lauric acid’s pharmacology is that of a dietary and structural lipid. The evidence splits by route and vehicle — in-vitro/topical antimicrobial work on the isolate, mechanistic anti-androgen data from the saw palmetto fatty-acid fraction, and robust human metabolic data that describe it as a cholesterol-raising dietary fat, not a supplement.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Scores mix a well-documented in-vitro antimicrobial property with mechanistic anti-androgen data and dietary metabolic effects, so read the per-row basis.

01Antimicrobial / anti-acne (topical, in vitro)Promising48%Consistent in-vitro/topical activity of the isolate + monolaurin ^{1,2,3,5Reference 1Kabara JJ et al. · 1972Fatty acids and derivatives as antimicrobial agentsView study →Reference 2Nakatsuji T et al. · 2009Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgarisView study →Reference 3Yang D et al. · 2009The antimicrobial activity of liposomal lauric acids against Propionibacterium acnesView study →Reference 5Welch JL et al. · 2020Glycerol monolaurate, an analogue to a factor secreted by Lactobacillus, is virucidal against enveloped viruses, including HIV-1. mBio. https://pubmed.ncbi.nlm.nih.gov/32371599/View study →}

02Dietary lipid & cardiovascular effectPromising46%Robust human metabolic-ward data — but a caution, not a benefit ^{6,7Reference 6Mensink RP et al. · 2003Meta-analysisEffects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trialsView study →Reference 7Eyres L et al. · 2016Coconut oil consumption and cardiovascular risk factors in humansView study →}

035α-reductase inhibition (saw palmetto fraction)Shaky30%In-vitro enzyme inhibition; efficacy belongs to the whole extract ^{10Reference 10Raynaud JP et al. · 2002Inhibition of type 1 and type 2 5α-reductase activity by free fatty acids, active ingredients of PermixonView study →}

Mechanisms

The load-bearing contrast is that lauric acid’s real, reproducible property is antimicrobial and largely in-vitro, while its most certain human effect is as a cholesterol-raising dietary fat — two different things that marketing tends to blur.

Pharmacokinetics

Lauric acid is a 12-carbon saturated fatty acid that occupies an intermediate metabolic position. As a component of dietary triglyceride it is released by lipases and absorbed in the small intestine; unlike the true medium-chain fats caprylic (C8) and capric (C10) acid — which travel unesterified via the portal vein to the liver — a large share of lauric acid (commonly cited ~70-75%) is re-esterified and packaged into chylomicrons for lymphatic transport, the long-chain route ^{11Reference 11Sigalet DL · 1999Lymphatic absorption of glucose and fatty acids as determined by direct measurementView study →}. This dual behaviour is why classifying it as an “MCT” is only half-right and why coconut oil does not reproduce purified MCT-oil kinetics ^{7,11Reference 7Eyres L et al. · 2016Coconut oil consumption and cardiovascular risk factors in humansView study →Reference 11Sigalet DL · 1999Lymphatic absorption of glucose and fatty acids as determined by direct measurementView study →}. Once circulating it is handled like other fatty acids — β-oxidised for energy, stored, or incorporated into membrane and structural lipids — and it exerts its cholesterol-raising effect through hepatic lipoprotein metabolism ^{6Reference 6Mensink RP et al. · 2003Meta-analysisEffects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trialsView study →}.

Clinical Trials

There are no clinical trials of isolated lauric acid as a therapeutic drug. Human evidence exists only for whole-oil diets — controlled feeding studies quantifying its effect on blood lipids ^{6,7Reference 6Mensink RP et al. · 2003Meta-analysisEffects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trialsView study →Reference 7Eyres L et al. · 2016Coconut oil consumption and cardiovascular risk factors in humansView study →} — and, indirectly, for saw palmetto extract in benign prostatic hyperplasia, where lauric acid is one fatty acid among many ^{10Reference 10Raynaud JP et al. · 2002Inhibition of type 1 and type 2 5α-reductase activity by free fatty acids, active ingredients of PermixonView study →}. Antimicrobial and anti-acne data are in-vitro or topical/preclinical ^{1,2,3,5Reference 1Kabara JJ et al. · 1972Fatty acids and derivatives as antimicrobial agentsView study →Reference 2Nakatsuji T et al. · 2009Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgarisView study →Reference 3Yang D et al. · 2009The antimicrobial activity of liposomal lauric acids against Propionibacterium acnesView study →Reference 5Welch JL et al. · 2020Glycerol monolaurate, an analogue to a factor secreted by Lactobacillus, is virucidal against enveloped viruses, including HIV-1. mBio. https://pubmed.ncbi.nlm.nih.gov/32371599/View study →}.

Last checked: July 2026.

Isolate vs. Plant Studies

The two ends of lauric acid’s evidence base use the molecule very differently. The antimicrobial and anti-acne data test the isolate — pure lauric acid or monolaurin on bacteria, viruses and skin cells — which is a strength for mechanism but stops at the Petri dish or the skin surface ^{1,2,3,5Reference 1Kabara JJ et al. · 1972Fatty acids and derivatives as antimicrobial agentsView study →Reference 2Nakatsuji T et al. · 2009Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgarisView study →Reference 3Yang D et al. · 2009The antimicrobial activity of liposomal lauric acids against Propionibacterium acnesView study →Reference 5Welch JL et al. · 2020Glycerol monolaurate, an analogue to a factor secreted by Lactobacillus, is virucidal against enveloped viruses, including HIV-1. mBio. https://pubmed.ncbi.nlm.nih.gov/32371599/View study →}. The human metabolic data, by contrast, come from feeding whole coconut oil or defined-fat diets, where lauric acid is the dominant but not the only fatty acid ^{6,7Reference 6Mensink RP et al. · 2003Meta-analysisEffects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trialsView study →Reference 7Eyres L et al. · 2016Coconut oil consumption and cardiovascular risk factors in humansView study →}. And its 5α-reductase role is studied as part of the whole saw palmetto lipophilic extract, not as an administered isolate ^{10Reference 10Raynaud JP et al. · 2002Inhibition of type 1 and type 2 5α-reductase activity by free fatty acids, active ingredients of PermixonView study →}. No human trial gives isolated lauric acid to treat a disease — so its clinical identity remains that of a food constituent, not a drug.

Prevalence in Nature

Lauric acid is unusual among fatty acids in being concentrated in only a few sources rather than spread thinly everywhere. By far its richest homes are the lauric oils: coconut oil (Cocos nucifera), where it is the single largest fatty acid at roughly 45-52% of the total, and palm-kernel oil (Elaeis guineensis) at a similar 45-50% ^{7,9Reference 7Eyres L et al. · 2016Coconut oil consumption and cardiovascular risk factors in humansView study →Reference 9Ghosh PK et al. · 2014Physicochemical and phytochemical analyses of copra and oil of Cocos nucifera L. (West Coast Tall variety)View study →}. Other palm fats such as babassu are comparable. It also appears in the berry oil of the laurel (Laurus nobilis) — the source of its name — and as a smaller component of the saw palmetto berry fatty-acid fraction (~26-32%) ^{10Reference 10Raynaud JP et al. · 2002Inhibition of type 1 and type 2 5α-reductase activity by free fatty acids, active ingredients of PermixonView study →}.

Beyond plants, lauric acid is a minor constituent of milk fats and of human breast milk, where medium-chain fatty acids contribute to the infant’s early antimicrobial defence — a natural parallel to its laboratory antimicrobial activity. It is largely absent from the common non-tropical seed and nut oils (sunflower, soybean, olive — the last dominated instead by monounsaturated oleic acid), which is why the lauric oils stand out.

Discovery & Synthesis

Lauric acid was known to nineteenth-century fat chemists as the principal fatty acid of laurel and coconut fats; its name derives from the laurel (Latin laurus), from whose berry oil it was early obtained, before it became identified overwhelmingly with coconut and palm-kernel oil. As a simple, abundant saturated fatty acid it required no “total synthesis” in the pharmaceutical sense — it is isolated directly from its natural oils.

Manufacture today is by hydrolysis (splitting) of coconut or palm-kernel oil followed by fractional distillation to separate the C12 fraction; the resulting lauric acid is a large-volume oleochemical feedstock for surfactants, soaps and, via its monoglyceride, food-grade antimicrobials. Its monoglyceride monolaurin (glycerol monolaurate) is made by esterifying lauric acid with glycerol. Little of the commercial supply is a synthetic molecule — it is a plant-oil derivative made at industrial scale.

Patents: not yet researched.

Toxicity & Safety

Lauric acid carries a low flag: it is a normal dietary fatty acid, consumed in gram quantities by anyone eating coconut or palm-kernel products, and is not acutely toxic. The one substantive caveat is nutritional, not toxicological — as a saturated fat it raises LDL cholesterol.

Safety at a Glance

✅ Low / no toxicity

• A normal dietary and structural fat. Consumed routinely from coconut, palm-kernel and dairy fats; no acute toxicity at food intakes; monolaurin has food-additive use.
• Raises LDL cholesterol. As a saturated fat, lauric acid raises total and LDL cholesterol (it also raises HDL); coconut-oil-rich diets show higher LDL than unsaturated-oil diets.
• The “MCT” and “antimicrobial” claims are overstated for food use. Its medium-chain metabolism is only partial, and the antimicrobial data are largely in-vitro/topical — not evidence that dietary coconut oil treats infection.

Full Safety & Interactions Detail

Dietary lipid effect. The best-characterised effect of lauric acid in humans is on blood lipids. In controlled feeding studies it raises total and LDL cholesterol relative to unsaturated fats or carbohydrate, while also raising HDL; on the total-cholesterol-to-HDL ratio it is somewhat less unfavourable than myristic (C14) or palmitic (C16) acid, but it does not lower LDL and does not qualify as a cardioprotective fat ^{6,7Reference 6Mensink RP et al. · 2003Meta-analysisEffects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trialsView study →Reference 7Eyres L et al. · 2016Coconut oil consumption and cardiovascular risk factors in humansView study →}. Public-health guidance therefore treats coconut and palm-kernel oil as saturated fats to limit, not as health oils.

Antimicrobial claims vs. reality. The antimicrobial and antiviral activity of lauric acid and monolaurin is real in vitro and topically ^{1,2,5Reference 1Kabara JJ et al. · 1972Fatty acids and derivatives as antimicrobial agentsView study →Reference 2Nakatsuji T et al. · 2009Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgarisView study →Reference 5Welch JL et al. · 2020Glycerol monolaurate, an analogue to a factor secreted by Lactobacillus, is virucidal against enveloped viruses, including HIV-1. mBio. https://pubmed.ncbi.nlm.nih.gov/32371599/View study →}, but this should not be read as evidence that eating coconut oil treats or prevents infection in people — that human evidence does not exist.

No isolate toxicology of concern. There is no significant genotoxicity, organ-toxicity or interaction signal for lauric acid as a dietary fatty acid at ordinary intakes; monolaurin is used as a food-grade emulsifier/antimicrobial. Formal drug-interaction and repeat-dose isolate packages were not assessed here — the compound’s exposure is dietary, and specific pharmaceutical-style interaction data are not established.

Reproductive note (prose only). Lauric acid is a natural component of breast milk and ordinary diet; no reproductive-toxicity concern attaches to dietary intake. Any pregnancy/lactation decision belongs to the herb or product page where intake is decided, not to this molecule page.

Dosage

There is no recommended supplemental dose of isolated lauric acid — it is a dietary and structural fatty acid, not a drug, and human exposure comes from food. To give a sense of scale, coconut oil is roughly 45-52% lauric acid ^{9Reference 9Ghosh PK et al. · 2014Physicochemical and phytochemical analyses of copra and oil of Cocos nucifera L. (West Coast Tall variety)View study →}, so a single tablespoon (~14 g) of coconut oil supplies on the order of 6-7 g of lauric acid; palm-kernel oil is similar ^{7Reference 7Eyres L et al. · 2016Coconut oil consumption and cardiovascular risk factors in humansView study →}.

Its monoglyceride monolaurin is sold as a supplement (typically several hundred milligrams to a few grams per day in product labelling), but the antimicrobial data behind those products are largely in vitro, so no effective human dose is established ^{1,5Reference 1Kabara JJ et al. · 1972Fatty acids and derivatives as antimicrobial agentsView study →Reference 5Welch JL et al. · 2020Glycerol monolaurate, an analogue to a factor secreted by Lactobacillus, is virucidal against enveloped viruses, including HIV-1. mBio. https://pubmed.ncbi.nlm.nih.gov/32371599/View study →}. Where lauric acid appears in saw palmetto products it is standardised as part of the whole lipophilic fatty-acid extract, not dosed as the isolate ^{10Reference 10Raynaud JP et al. · 2002Inhibition of type 1 and type 2 5α-reductase activity by free fatty acids, active ingredients of PermixonView study →}. These are dietary and research figures, not a personal recommendation.

References

1. Kabara JJ, Swieczkowski DM, Conley AJ, Truant JP (1972). Fatty acids and derivatives as antimicrobial agents. Antimicrobial Agents and Chemotherapy. https://pubmed.ncbi.nlm.nih.gov/4670656/
2. Nakatsuji T, Kao MC, Fang JY, et al. (2009). Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris. Journal of Investigative Dermatology. https://pubmed.ncbi.nlm.nih.gov/19387482/
3. Yang D, Pornpattananangkul D, Nakatsuji T, et al. (2009). The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes. Biomaterials. https://pubmed.ncbi.nlm.nih.gov/19665786/
4. Nakatsuji T, Kao MC, Zhang L, et al. (2010). Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating β-defensin-2 expression. Journal of Investigative Dermatology. https://pubmed.ncbi.nlm.nih.gov/20032992/
5. Welch JL, Xiang J, Okeoma CM, et al. (2020). Glycerol monolaurate, an analogue to a factor secreted by Lactobacillus, is virucidal against enveloped viruses, including HIV-1. mBio. https://pubmed.ncbi.nlm.nih.gov/32371599/
6. Mensink RP, Zock PL, Kester AD, Katan MB (2003). Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. American Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/12716665/
7. Eyres L, Eyres MF, Chisholm A, Brown RC (2016). Coconut oil consumption and cardiovascular risk factors in humans. Nutrition Reviews. https://pubmed.ncbi.nlm.nih.gov/26946252/
8. Kris-Etherton PM, Derr J, Mitchell DC, et al. (1993). The role of fatty acid saturation on plasma lipids, lipoproteins, and apolipoproteins: I. Effects of whole food diets high in cocoa butter, olive oil, soybean oil, dairy butter, and milk chocolate. Metabolism. https://pubmed.ncbi.nlm.nih.gov/8446039/
9. Ghosh PK, Bhattacharjee P, Mitra S, Poddar-Sarkar M (2014). Physicochemical and phytochemical analyses of copra and oil of Cocos nucifera L. (West Coast Tall variety). International Journal of Food Science. https://pubmed.ncbi.nlm.nih.gov/26904626/
10. Raynaud JP, Cousse H, Martin PM (2002). Inhibition of type 1 and type 2 5α-reductase activity by free fatty acids, active ingredients of Permixon. Journal of Steroid Biochemistry and Molecular Biology. https://pubmed.ncbi.nlm.nih.gov/12477490/
11. Sigalet DL, Martin GR (1999). Lymphatic absorption of glucose and fatty acids as determined by direct measurement. Journal of Pediatric Surgery. https://pubmed.ncbi.nlm.nih.gov/10022140/

View all 11 references▾